Loading...
XTAI
1733
Market cap105mUSD
May 23, Last price  
31.50TWD
1D
1.29%
1Q
1.94%
Jan 2017
-23.73%
Name

Apex Biotechnology Corp

Chart & Performance

D1W1MN
P/E
24.60
P/S
1.70
EPS
1.28
Div Yield, %
3.49%
Shrs. gr., 5y
-2.37%
Rev. gr., 5y
-3.37%
Revenues
1.85b
+10.48%
1,438,917,0001,749,690,0001,876,273,0002,026,086,0001,829,221,0001,788,929,0001,847,454,0001,763,284,0001,795,300,0002,043,614,0002,198,862,0002,005,337,0002,131,656,0002,244,176,0001,676,537,0001,852,211,000
Net income
128m
+10.55%
326,483,000453,949,000526,617,000522,710,000371,221,000273,377,000261,853,0003,181,00085,553,00095,119,000113,859,00094,795,000202,224,000181,785,000115,783,000127,998,000
CFO
329m
+42.66%
391,286,000465,587,000273,447,000509,665,000484,767,000267,604,000472,152,000298,057,00070,828,00067,566,000462,523,000280,603,000179,868,00026,616,000230,391,000328,669,000
Dividend
May 17, 20241.1 TWD/sh

Profile

Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing, and hemoglobin screening systems. It also provides pesticide residues check systems; and care management and tele-health services. The company was founded in 1997 and is headquartered in Hsinchu City, Taiwan.
URL
https://www.apexbio.com.tw/
IPO date
Sep 17, 2001
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,852,211
10.48%
1,676,537
-25.29%
2,244,176
5.28%
Cost of revenue
1,723,702
1,533,004
2,067,616
Unusual Expense (Income)
NOPBT
128,509
143,533
176,560
NOPBT Margin
6.94%
8.56%
7.87%
Operating Taxes
25,023
25,248
18,124
Tax Rate
19.47%
17.59%
10.27%
NOPAT
103,486
118,285
158,436
Net income
127,998
10.55%
115,783
-36.31%
181,785
-10.11%
Dividends
(109,945)
(139,930)
(129,935)
Dividend yield
3.64%
3.46%
5.05%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
52,233
64,635
121,239
Long-term debt
236,884
239,592
253,350
Deferred revenue
Other long-term liabilities
465
477
485
Net debt
(249,768)
(84,019)
36,684
Cash flow
Cash from operating activities
328,669
230,391
26,616
CAPEX
(28,244)
(21,914)
(40,200)
Cash from investing activities
(35,598)
(22,497)
(41,366)
Cash from financing activities
(148,669)
(168,141)
(237,602)
FCF
270,872
183,668
(63,275)
Balance
Cash
598,784
443,914
397,534
Long term investments
(59,899)
(55,668)
(59,629)
Excess cash
446,274
304,419
225,696
Stockholders' equity
1,216,099
1,768,772
1,789,731
Invested Capital
1,544,584
1,673,823
1,799,674
ROIC
6.43%
6.81%
9.51%
ROCE
6.44%
7.26%
8.70%
EV
Common stock shares outstanding
100,221
100,326
100,671
Price
30.10
-25.31%
40.30
57.73%
25.55
-1.73%
Market cap
3,016,658
-25.39%
4,043,138
57.19%
2,572,144
-6.35%
EV
2,767,524
3,959,619
2,609,397
EBITDA
193,319
219,243
270,660
EV/EBITDA
14.32
18.06
9.64
Interest
3,642
4,388
5,398
Interest/NOPBT
2.83%
3.06%
3.06%